HOLOGIC INC shareholders Q2 2024

HOLOGIC INC's ticker is HOLX and the CUSIP is 436440101. A total of 683 filers reported holding HOLOGIC INC in Q2 2024. The put-call ratio across all filers is 0.44 and the average weighting 0.1%.

HOLOGIC INC shareholders Q2 2024
NameSharesValueWeighting ↓
Gotham Asset Management, LLC 221,288$16,430,6340.21%
True Wealth Design, LLC 11,576$859,5180.21%
J. W. Coons Advisors, LLC 11,700$868,7250.21%
TWIN CAPITAL MANAGEMENT INC 23,758$1,764,0320.21%
CUSTOM INDEX SYSTEMS, LLC 4,864$361,1520.21%
PARNASSUS INVESTMENTS, LLC 1,273,829$94,581,8030.21%
BECKER CAPITAL MANAGEMENT INC 79,134$5,875,7000.20%
Fox Hill Wealth Management 4,398$326,5520.20%
DekaBank Deutsche Girozentrale 1,482,871$109,6640.20%
Bayesian Capital Management, LP 23,034$1,710,2750.20%
NICHOLAS COMPANY, INC. 155,480$11,544,3900.19%
TRILLIUM ASSET MANAGEMENT, LLC 102,284$7,595,0000.19%
WESTPAC BANKING CORP 31,664$2,351,0520.19%
Illinois Municipal Retirement Fund 162,548$12,069,1890.18%
SENTINEL TRUST CO LBA 20,000$1,4850.18%
One Charles Private Wealth Services, LLC 5,850$434,3630.18%
BDF-GESTION 25,211$1,871,9170.18%
Triodos Investment Management BV 27,500$2,041,8750.18%
Kades & Cheifetz LLC 3,772$280,0710.18%
State of Alaska, Department of Revenue 211,499$15,7030.18%
About HOLOGIC INC

Hologic Inc: A Leader in Women's Health

Hologic Inc is a medical technology company that specializes in women's health. The company is headquartered in Marlborough, Massachusetts, and has operations in over 50 countries worldwide. Hologic's mission is to improve women's health through early detection and treatment of diseases such as breast cancer, cervical cancer, and osteoporosis.

Hologic's flagship product is the Genius 3D Mammography system, which is the first and only FDA-approved 3D mammography system. The system provides better detection of breast cancer than traditional 2D mammography, and reduces the need for additional imaging and biopsies. Hologic also offers a range of other products for breast cancer screening and diagnosis, including breast biopsy systems and breast MRI coils.

In addition to breast health, Hologic also offers products for cervical cancer screening, such as the ThinPrep Pap test and the Aptima HPV assay. The company also offers products for osteoporosis diagnosis and treatment, including the Horizon DXA system and the Fluoroscan InSight FD mini C-arm.

Hologic has a strong commitment to research and development, with over 1,200 patents and patent applications worldwide. The company invests heavily in clinical studies to ensure the safety and efficacy of its products, and has a team of over 1,000 scientists and engineers working to develop new technologies.

Overall, Hologic is a leader in women's health, with a strong focus on early detection and treatment of diseases. The company's innovative products and commitment to research make it a valuable partner for healthcare providers and patients alike.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists HOLOGIC INC's shareholders in Q2 2024. To view HOLOGIC INC's shareholder history, click here.